Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.32 USD | -2.60% | +4.62% | +5.87% |
Nov. 01 | Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $62 From $60 | MT |
Nov. 01 | JPMorgan Chase Adjusts Price Target on Bristol-Myers Squibb to $64 From $60 | MT |
Business description: Bristol-Myers Squibb Company
The United States account for 70.1% of net sales.
Number of employees: 34,100
Sales by Activity: Bristol-Myers Squibb Company
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Pharmaceuticals | 26.14B | 42.52B | 46.38B | 46.16B | 45.01B |
Geographical breakdown of sales: Bristol-Myers Squibb Company
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
United States | 15.34B | 26.58B | 29.21B | 31.83B | 31.56B |
International | - | - | - | 13.5B | 12.75B |
Unallocated | 524M | 631M | 852M | 834M | 699M |
Europe | 6.27B | 9.85B | 10.69B | - | - |
Rest of The World | 4.01B | 5.46B | 5.63B | - | - |
Managers: Bristol-Myers Squibb Company
Director | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 2023-10-31 | |
David Elkins
DFI | Director of Finance/CFO | 56 | 2019-11-19 |
Chief Tech/Sci/R&D Officer | - | - | |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 2023-09-30 |
Members of the board: Bristol-Myers Squibb Company
Manager | Title | Age | Since |
---|---|---|---|
Chairman | 53 | 2024-03-31 | |
Peter Arduini
BRD | Director/Board Member | 59 | 2016-03-31 |
Theodore Samuels
BRD | Director/Board Member | 69 | 2017-02-20 |
Karen Vousden
BRD | Director/Board Member | 66 | 2017-12-31 |
Julia Haller
BRD | Director/Board Member | 69 | 2019-11-19 |
Phyllis Yale
BRD | Director/Board Member | 66 | 2019-11-19 |
Paula Price
BRD | Director/Board Member | 62 | 2020-08-31 |
Derica Rice
BRD | Director/Board Member | 59 | 2020-08-31 |
Director/Board Member | 56 | 2021-05-31 | |
Deepak Bhatt
BRD | Director/Board Member | 56 | 2022-06-13 |
Holdings: Bristol-Myers Squibb Company
Name | Equities | % | Valuation |
---|---|---|---|
5,075,304 | 4.33% | 233,108,713 $ | |
PRIME MEDICINE, INC. 9.17% | 11,006,163 | 9.17% | 42,593,851 $ |
PRIME MEDICINE, INC. 6.29% | 759,145 | 6.29% | 33,873,050 $ |
70,231,140 | 16.92% | 16,726,951 $ | |
COMPUGEN LTD. 5.31% | 4,757,058 | 5.31% | 8,610,275 $ |
CELULARITY INC. 5.49% | 1,195,327 | 5.49% | 3,550,121 $ |
Company details: Bristol-Myers Squibb Company
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comGroup companies: Bristol-Myers Squibb Company
Name | Category and Sector |
---|---|
Bristol-Myers Squibb SA (Spain)
|
Medical Distributors
|
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
| |
Bristol-Myers Squibb (Finland) Oy Ab
Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Other Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
---|---|---|---|---|---|---|
-2.60% | +4.62% | +6.24% | -7.35% | 110B | ||
-1.30% | -8.26% | +41.12% | +218.84% | 736B | ||
+0.76% | -1.96% | +8.37% | +115.38% | 496B | ||
+0.17% | -0.47% | +6.58% | -3.30% | 386B | ||
-0.16% | +8.36% | +42.08% | +74.68% | 360B | ||
-0.43% | -2.02% | -0.94% | +14.45% | 258B | ||
+1.94% | -2.88% | +14.68% | -25.68% | 253B | ||
-0.18% | -5.03% | +6.37% | +16.92% | 221B | ||
+1.80% | -3.21% | +12.79% | +24.27% | 219B | ||
-0.29% | +0.71% | +19.74% | +48.99% | 172B | ||
Average | -0.03% | -1.01% | +15.70% | +47.72% | 321.12B | |
Weighted average by Cap. | -0.05% | -2.08% | +19.89% | +80.29% |
Sector
- Stock Market
- Equities
- BMY Stock
- Company Bristol-Myers Squibb Company